Watson Pharmaceuticals Inc

Type: Company
Name: Watson Pharmaceuticals Inc
First reported 15 hours ago - Updated 12 hours ago - 1 reports

Impax Labs names G. Frederick Wilson as president, CEO

HAYWARD, Calif. — Impax Labs on Monday announced the its board of directors appointed G. Frederick Wilson as the company's president and CEO, effective April 29, 2014. Wilkinson previously served as president of Actavis Global Research and Development ... [Published Drug Store News - 15 hours ago]
First reported Apr 21 2014 - Updated Apr 21 2014 - 5 reports

Impax names G. Frederick Wilkinson as CEO

Impax Laboratories announced Monday that its board appointed G. Frederick Wilkinson to the post of president and CEO of the company as of April 29. Wilkinson, who will leave his role as president of global R&D for Actavis on April 25, succeeds Larry Hsu, ... [Published FirstWord Pharma - Apr 21 2014]
First reported Apr 20 2014 - Updated Apr 20 2014 - 1 reports

RECLIPSEN (Desogestrel And Ethinyl Estradiol) Kit [Watson Pharma, Inc.]

First reported Apr 17 2014 - Updated Apr 17 2014 - 1 reports

Impax Laboratories appoints senior vice president of technical operations

Impax Laboratories, Inc., a pharmaceutical company, has appointed Jeffrey Nornhold as senior vice president of technical operations and will oversee the company's manufacturing, supply chain, quality and technical operations. Mr Nornhold previously served ... [Published Individual.com - Apr 17 2014]
First reported Apr 15 2014 - Updated Apr 15 2014 - 1 reports

Impax believes manufacturing issues are fixed

Drug developer seeks approval for Rytary; first app was sidelined by plant problemsShareToolsImpax Laboratories ($IPXL) had its future sidelined by manufacturing problems that set off a domino effect. The issues kept the FDA from considering its application ... [Published FiercePharmaManufacturing - Apr 15 2014]
First reported Apr 14 2014 - Updated Apr 15 2014 - 1 reports

UPDATE 1-Akorn gets U.S. approval to buy Hi-Tech Pharmacal, with conditions

Generic drugmaker AkornEnterprises Inc has won U.S. antitrust approval to buyrival Hi-Tech Pharmacal Inc on condition that it sellthree generic prescription eye medications and two generictopical anesthetics, the Federal Trade Commission said onMonday. ... [Published Reuters - Apr 14 2014]
First reported Apr 10 2014 - Updated Apr 10 2014 - 1 reports

Shire Development, LLC v. Watson Pharmaceuticals, Inc. (Fed. Cir. 2014)

Claim construction in patent cases, and the propensity for the Federal Circuit to disagree with a district court's conclusions regarding the scope and meaning of claim terms, remains one of the most vexing aspects of patent litigation (yes, even more ... [Published JD Supra - Apr 10 2014]
First reported Apr 10 2014 - Updated Apr 10 2014 - 1 reports

Shire Development, LLC v. Watson Pharmaceuticals, Inc. (Fed. Cir. 2014)

By Kevin E. Noonan -- Claim construction in patent cases, and the propensity for the Federal Circuit to disagree with a district court's conclusions regarding the scope and meaning of claim terms, remains one of the most vexing aspects of patent litigation ... [Published Patent Docs - Apr 10 2014]
First reported Apr 05 2014 - Updated Apr 05 2014 - 1 reports

Half of U.S. adults ages 40 to 75 are eligible for cholesterol-lowering drugs

This 2011 photo provided by Watson Pharmaceuticals Inc. shows bottles of Atorvastatin calcium tablets, a generic form of Lipitor that is sold under a deal with Pfizer. Half of Americans ages 40 to 75 and nearly all men over 60 qualify to consider cholesterol-lowering ... [Published Texarkana Gazette - Apr 05 2014]
First reported Apr 02 2014 - Updated Apr 03 2014 - 2 reports

Impax Labs Names Technical Ops SVP

Jeffrey D. Nornhold has been appointed senior vice president of Technical Operations at Impax Laboratories, Inc . Mr. Nornhold will oversee the company's manufacturing, supply chain, quality and technical operations. He previously served as senior vice ... [Published Contract Pharma - Apr 02 2014]
First reported Apr 01 2014 - Updated Apr 02 2014 - 1 reports

Actavis plans to spend $100M on generic drugmaker

Drugmaker Actavis Plc plans to expand its reach into Southeast Asia by spending about $100 million to buy Silom Medical Co., a generic pharmaceutical company focused on Thailand.Actavis, based in Ireland, said its latest deal should help adjusted earnings ... [Published CNBC - Apr 01 2014]
First reported Mar 28 2014 - Updated Mar 28 2014 - 2 reports

US wants at least $1 billion from drugmakers who delay generics

Deborah Feinstein, director of the US Federal Trade Commission's Bureau of Competition suggested that the agency is seeking a settlement of $1 billion or more from pharmaceutical companies it has sued for delaying the sale of generic medicines, as reported ... [Published FirstWord Pharma - Mar 28 2014]

Quotes

Zacks’ analyst wrote, "Actavis’ fourth quarter results were strong with EPS coming in at $3.17, well above the Zacks Consensus Estimate of $3.06 and 99.4% above the year-ago EPS. Revenues came in at $2.779 billion, up 58.8% from the year-ago period, and slightly above the Zacks Consensus Estimate of $2.707 billion. However, results were overshadowed by the company’s decision to acquire Forest. This decision is in line with Actavis’ strategy of building its branded product portfolio. With a fewer number of blockbuster products slated to lose patent protection in the coming years, quite aa few generic companies have been focusing on strengthening their branded products offerings. We remain optimistic about Actavis’ growth prospects and maintain our Outperform recommendation. "
...advancing pipeline products and driving innovation, make him the perfect candidate for this role," said Robert L Burr, Chairman of Impax Labs. "I have every confidence that Fred's vision and passion will translate into remarkable success for Impax. The Board would like to thank Dr. Hsu for his incredible dedication and commitment over the last 18 years and for positioning the company for its next phase of growth."
...future direction of the company and reinforce a quality-first culture," Wilkinson said in a statement on his new role as Impax president and CEO. "This is a great company, with a strong balance sheet, experienced business team and multiple product opportunities. I look forward to building on Impax's success."
...rganization and establishing the foundation for sustainable quality and compliance", said Larry Hsu, Ph D , President and CEO of Impax Laboratories. "We believe Jeff is the ideal person to manage this new structure, and effectively drive compliance, efficiencies and collaboration across these key business functions."

More Content

All (60) | News (51) | Reports (0) | Blogs (5) | Audio/Video (0) | Fact Sheets (4) | Press Releases (0)
sort by: Date | Relevance
Actavis plc Receives “Outperform” Rating from Z... [Published American Banking News - 9 hours ago]
Impax Labs names G. Frederick Wilson as preside... [Published Drug Store News - 15 hours ago]
Dermatological Drugs Market Forecast 2014-2024 [Published Individual.com - 19 hours ago]
Impax names G. Frederick Wilkinson as CEO [Published FirstWord Pharma - Apr 21 2014]
Impax hires Actavis exec as CEO [Published Chain Drug Review - Apr 21 2014]
Impax Laboratories picks Frederick Wilkinson as... [Published Business First of Buffalo - Apr 21 2014]
Impax Labs Appoints Frederick Wilkinson As Pres... [Published RTTNews.com - Apr 21 2014]
Impax Laboratories : Board of Directors Appoint... [Published 4 Traders - Apr 21 2014]
RECLIPSEN (Desogestrel And Ethinyl Estradiol) K... [Published DailyMed Drug Label Updates for the last seven ... - Apr 20 2014]
Actavis plc Coverage Initiated by Analysts at ... [Published Mideast Time - Apr 18 2014]
Impax Laboratories appoints senior vice preside... [Published Individual.com - Apr 17 2014]
Actavis plc Now Covered by National Alliance S... [Published American Banking News - Apr 17 2014]
Actavis plc Now Covered by Sterne Agee (ACT) [Published American Banking News - Stock Ratings - Apr 16 2014]
Impax believes manufacturing issues are fixed [Published FiercePharmaManufacturing - Apr 15 2014]
UPDATE 1-Akorn gets U.S. approval to buy Hi-Tec... [Published Reuters - Apr 14 2014]
Shire Development, LLC v. Watson Pharmaceutical... [Published JD Supra - Apr 10 2014]
Shire Development, LLC v. Watson Pharmaceutical... [Published Patent Docs - Apr 10 2014]
Buy Actavis - An Attractive Value And Growth Pl... [Published Seeking Alpha - Apr 10 2014]
Actavis plc Upgraded to Positive at Susquehann... [Published Mideast Time - Apr 09 2014]
Actavis plc Target of Unusually Large Options ... [Published American Banking News - Forex - Apr 08 2014]
CorMedix Inc. Welcomes Additional Board Members [Published Barchart - Apr 07 2014]
Half of U.S. adults ages 40 to 75 are eligible ... [Published Texarkana Gazette - Apr 05 2014]
Impax Labs Names Technical Ops SVP [Published Contract Pharma - Apr 02 2014]
Impax Laboratories Announces the Alignment of Q... [Published ADVFN India - Apr 02 2014]
Actavis plans to spend $100M on generic drugmaker [Published CNBC - Apr 01 2014]
Actavis plc Receives Average Recommendation of... [Published American Banking News - Apr 01 2014]
Recent patent cases from the Federal Circuit - ... [Published Lexology - Apr 01 2014]
Mealey's IP/Tech - Federal Circuit Reverses Inf... [Published Mealey - Mar 31 2014]
Androderm Lawsuit Filed in California Court Aft... [Published HG.org - Mar 31 2014]
US wants at least $1 billion from drugmakers wh... [Published FirstWord Pharma - Mar 28 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
RECLIPSEN (Desogestrel And Ethinyl Estradiol) K... [Published DailyMed Drug Label Updates for the last seven ... - Apr 20 2014]
Updated Date: Apr 16, 2014 EST ...
Shire Development, LLC v. Watson Pharmaceutical... [Published Patent Docs - Apr 10 2014]
By Kevin E. Noonan -- Claim construction in patent cases, and the propensity for the Federal Circuit to disagree with a district court's conclusions regarding the scope and meaning of claim terms, remains one of the most vexing aspects of patent litigation ...
HYDROCODONE BITARTRATE AND ACETAMINOPHEN Tablet... [Published DailyMed Drug Label Updates for the last seven ... - Mar 22 2014]
Updated Date: Mar 18, 2014 EST ...
HYDROCODONE BITARTRATE AND ACETAMINOPHEN Tablet... [Published DailyMed Drug Label Updates for the last seven ... - Mar 18 2014]
Updated Date: Mar 18, 2014 EST ...
Deals Of The Week: Novartis Places Bid To Domin... [Published The IN VIVO Blog - Feb 21 2014]
While the largest deal of the week, and certainly the one receiving the most attention, has been Actavis' expansion of its branded portfolio via its $25 billion purchase of Forest Laboratories, the deal that could have major implications for a hot ...
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.